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Abstract
Each year, during winter months, human Metapneumovirus (hMPV) is associated with epidemics of bronchiolitis resulting in
the hospitalization of many infants. Bronchiolitis is an acute illness of the lower respiratory tract with a consequent
inflammation of the bronchioles. The rapid onset of inflammation suggests the innate immune response may have a role to
play in the pathogenesis of this hMPV infection. Since, the matrix protein is one of the most abundant proteins in the
Paramyxoviridae family virion, we hypothesized that the inflammatory modulation observed in hMPV infected patients may
be partly associated with the matrix protein (M-hMPV) response. By western blot analysis, we detected a soluble form of M-
hMPV released from hMPV infected cell as well as from M-hMPV transfected HEK 293T cells suggesting that M-hMPV may be
directly in contact with antigen presenting cells (APCs) during the course of infection. Moreover, flow cytometry and
confocal microscopy allowed determining that M-hMPV was taken up by dendritic cells (moDCs) and macrophages inducing
their activation. Furthermore, these moDCs enter into a maturation process inducing the secretion of a broad range of
inflammatory cytokines when exposed to M-hMPV. Additionally, M-hMPV activated DCs were shown to stimulate IL-2 and
IFN-c production by allogeneic T lymphocytes. This M-hMPV-mediated activation and antigen presentation of APCs may in
part explain the marked inflammatory immune response observed in pathology induced by hMPV in patients.
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Introduction
Human Metapneumovirus (hMPV), a member of the Pneumovir-
idae subfamily of Paramyxoviridae, has been recognized as a leading
cause of acute respiratory disease in children worldwide [1].
Studies have shown that hMPV infects approximately half of all
infants under the age of 1 year and that this figure increases to
virtually all children by the age of 10 [2,3]. Clinically, hMPV-
associated disease includes rhinitis, pharyngitis, bronchitis, bron-
chiolitis and pneumonia, and resembles that of human respiratory
syncytial virus (RSV) infection [4–6]. However, the immune
mechanisms and viral pathogenesis of respiratory illness related to
hMPV infection are not well understood and many questions
remain unanswered. Nevertheless, a widely accepted hypothesis is
that the pathogenesis of viral infection in the lower respiratory
tract of infants is due to the induction of innate inflammatory
responses [7–9]. This is supported by the observation that
inflammatory cytokines are detected in the nasopharyngeal and
the tracheal secretions of children with respiratory disease induced
by viral infection [10].
DCs are the most influential APC [11] residing in nearly all
peripheral tissues, including the respiratory tract, and are vital in
the early response to pathogens [12], such as the paramyxovirus
hMPV. Similarly, alveolar macrophages which are also APCs, are
capable of inducing a pro-inflammatory cascade in response to
viruses [13]. With this in mind, understanding the outcomes of
interactions between viruses, such as hMPV, and mucosal APCs is
critical to understand disease pathogenesis.
A characteristic of the paramyxovirus family is that they have a
lipid envelope containing two membrane glycoproteins: an
attachment glycoprotein (G) and a fusion protein (F). The
nucleocapsid core contains the viral RNA genome as well as the
nucleocapsid (N), phospho- (P), and large (L) proteins [14].
Between the envelope and the core resides what has been
described as one of the most abundant proteins of the virion:
the viral matrix (M) protein [15]. The M protein appears to play
two key roles: firstly, it inhibits the transcriptase activity of the
nucleocapsid prior to packaging and, secondly, the M protein
mediates the association of the nucleocapsid with the cell plasma
membrane [15–18]. All paramyxovirus M proteins are known to
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are presumed to play a crucial role in virus assembly and budding
[19]. The M protein of RSV has been observed in HEp2 infected
cells [20] throughout the cells and in cytoplasmic inclusions. It
suggests that this M protein can be released from these infected
cells in case of cell death or by an active process. M-hMPV may
then possibly generate signals that influence the immune response.
To date, M protein functions, have been described [20–22] but the
role played by these M protein in the immune process needs
further investigations, particularly in regard to the modulation of
the immune response.
In the present study, we show that the M-hMPV protein can be
released in a soluble form and in vitro, human macrophages and
DCs can be activated by the recombinant M-hMPV protein. Our
findings provide new insights about the role of M-hMPV protein
in the modulation of the immune response to virus and may
provide information to support a better understanding of hMPV
pathogenesis.
Materials and Methods
Viral preparation
The hMPV strain stock NL/1/00 corresponding to supernatant
and cells was obtained from Pr. A.D.M.E Osterhaus and Dr. J.
Simon at ViroNovative B.V., Rotterdam, The Netherlands.
Briefly, Vero cells were infected with the hMPV/NL/1/00 [1]
at MOI 1, incubated at 34uC and cultured in IMDM (minimal
essential medium) (Invitrogen) in the presence of glutamine
(2 mM), 0.3% BSA, 0.000375% trypsin, penicillin 100 U/mL
and streptomycin 100 mg/mL (Invitrogen). Vero cells were
maintained in IMDM supplemented with 10% fetal calf serum
(FCS), 2 mM L-glutamine, penicillin 100 U/mL and streptomycin
100 mg/mL antibiotics (all from Invitrogen).
M-hMPV protein capture experiment
M-hMPV protein was detected from supernatant of hMPV
infected Vero cells using positively charged magnetic beads
obtained from Dr. R. Veyret, bioMe ´rieux, Lyon, France [23].
Briefly, 1 mL of infected Vero cells supernatant was recovered
after 11 days of infection (first observation of the cytopathic effect),
ultracentrifugated (250 000 rpm at 4uC for 3 h in a Beckman
SW41 rotor ultracentrifuge) and then incubated with 10 mgo f
magnetic beads for 10 min. Magnetic beads were then recovered
by using a magnet and the preparation was analyzed by western
blot.
Western blotting
Western blotting was performed by using 1 mg/mL 8D12F6
and 1D7A7 monoclonal antibodies directed against M-hMPV (in
house validated antibodies, bioMe ´rieux). The membrane was
washed 10 min, three times in PBS-T and then incubated for 1 h
at room temperature with 1 mg/mL goat anti-mouse immuno-
globulin G horseradish peroxydase antibody (Promega). After
three washes in PBS-T for 10 min each time, the membrane was
developed by ECL-Western blotting detection reagents (AP
Biotech, Piscataway, NJ) according to the manufacturer’s
instructions and exposed to Kodak X-OMAT film for 45 min.
Expression and purification of hMPV matrix protein in
bacteria
cDNA was obtained from a RNA sample extracted using the
Nuclisens kit (bioMe ´rieux) from nasal swab of children mono-
infected by hMPV genotype A1 and hospitalized with bronchiol-
itis. The M-hMPV (nucleotides 2165–2929) was expressed in
E. coli and purified as described previously [24]. The amplification
of the M protein genomic sequence corresponding to amino acids
1–253 was achieved by reverse transcriptase-PCR (RT-PCR).
Briefly, the RT step was performed with primer 59-ATG-
GAGTCCTACCTAGTAGA-39 using Thermoscript RT kit
(Invitrogen) (70uC–8 min, 58u–1 h, 95uC–5 min, 4uC) followed
by two complementary PCR assays using the taq polymerase high
fidelity kit with primers 59-ATGGAGTCCTACCTAGTAGA-39
and 59-TCTGGACTTCAAGACATATC-39 (95uC–2 min,
95uC–30 sec, 52uC–1 min, 68uC–1 min, 68uC–7 min, 4uC for
30 cycles) and 59-CTCTCTGCTAGCGAGTCCTA CCTAG-
TAGACACCTATCAAGG-39C and 59-CTCTCTGGATCCT-
TAGTGGT GATGGTGATGGTGAGAACCC CTCATTCT-
GGACCTCAAGAC ATATCT-39, (95uC–2 min, 95uC–30 sec,
60uC–1 min, 68uC–1 min, 68uC–7 min, 4uC for 30 cycles). These
primers introduce a MRGS-6xHis tag at the C-terminal end. The
NheI and BamHI (underlined) digested PCR products were ligated
into the digested pET21-b expression vector (Novagen). E. coli
BL21DE3 bacteria containing recombinant pET21-b/M-hMPV
was grown until the OD600 reached 0.6 and induced with 0.4 mM
isopropyl-beta-D-thiogalactopyranoside. After 3 h, bacteria cells
were centrifuged and resuspended in a lysis buffer, disrupted by
sonication (3610 s–30 watts), followed by further centrifugation.
M-hMPV protein was absent from supernatant and was then
extracted from pelleted bacteria by a 6M urea buffer. This was
then applied on Ni-NTA Agarose (Qiagen) for purification
according to the manufacturer’s instructions in endotoxin-free
conditions. 6xHis-tagged recombinant M-hMPV protein was
eluted from the column by a pH gradient. Analysis of eluted
fraction was performed with Coomassie brilliant blue staining after
electrophoresis on 12% SDS-polyacrylamide gel under reducing
conditions.
Mass spectrometry analysis was completed using MALDI-TOF
in a voyager-DE-PRO (Applied Bio- systems, CA, USA) and only
the M-hMPV protein was observed.
The endotoxins concentration of the purified M-hMPV was
determined by a kinetic chromogenic-QCL Bio Wittaker Limulus
amoebocyte lysate assay at Laboratoire Marcel Me ´rieux (Lyon,
France) and was negative (,0.25 U endotoxins/mg of M-hMPV
protein). The RNA contaminants detection was performed by
RNA Array 6000 Pico kit from Agilent (Agilent Technologies) and
by detection of RNA 16S with universal PCR Light Cycler Fast
Start Master SYBR Green I. The protein M-hMPV preparation
did not contain RNA contaminants. The M-hMPV protein was
labeled by using Fluorescein-NHS (Pierce) and the preparation
controlled for the absence of endotoxins. Free fluorescein was
removed by dialysis and labeled protein was filtered at 22 mM and
recovered in PBS/SDS 0.01%/Azide 0.9 g/L.
Molecular cloning of eukaryotic M-hMPV protein and
transfection of HEK 293T cells
T h eM - h M P Vc o d i n gs e q u e n c ew a sc l o n e di n t ot h ev e c t o r
phCMV in BamHI restriction site. M-hMPV sequence was amplified
from bacterial expression plasmid pET21b/M-hMPV by PCR using
primer introducing BamHI restriction site: 59-CTAGGATCCCAC-
CATGGCTAGCGAGTCCTAC-39 and 59-CTAGGATCCT-
TATCTGGACTTCAAGACATATC-39. phCMV/M-hMPV was
transfected in HEK293T cells [25]. HEK 293T cellswere cultured at
37uC in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% FCS (Perbio). Cellsweregrown in75 cm
2flask to a
confluence of 60%. Transfection was performed using FuGENE HD
(Roche) according to the manufacturer’s instructions. Briefly, 10 mg
of DNA was diluted in 1000 mL of serum-free DMEM, and 30 mLo f
FuGENE HD was added to the diluted DNA. After 15 min of
Immune Response to M-hMPV
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In Vitroincubation, the mixture was added to the cells and incubated for 6 h
at 37uC. Then, 30 mL of DMEM supplemented with 10% FCS was
added to the cells.
M protein release assay and production of soluble M-
hMPV in eukaryotic cells
48 h after transfection, the cells supernatant was harvested and
centrifuged (5 min, 1 000 g,4 uC) to remove cellular debris. The
clarified supernatant was loaded on a 20% sucrose cushion and
centrifuged at 250 000 rpm at 4uC for 3 h in a Beckman SW41
rotor ultracentrifuge. After ultracentrifugation the upper phase
containing soluble protein was harvested and the pellet was
resuspended in 1 mL of PBS.
Flotation assay. Supernatant of M-hMPV transfected cells was
adjusted to 60% histodenz (Sigma) wt/wt, loaded at the bottom of
a tube, and layered with 8 mL 40% histodenz and 2 mL of 10%
histodenz. Tubes were centrifuged for 20 h at 250 000 rpm in a
Beckman SW41 rotor.
Generation of monocyte-derived DCs (moDCs) and
monocyte-derived macrophages (MDMs)
Human peripheral blood from healthy donors was obtained
from the Etablissement Franc ¸ais du Sang (Lyon, France).
Mononuclear cells were isolated by density gradient centrifugation
using Ficoll-Hypaque, and then centrifuged on a 50% Percoll
solution (Amersham Biosciences). Two fractions were recovered:
monocytes were purified from the light density fraction and T
lymphocytes from the high density fraction. The purification of
monocytes and lymphocytes were performed by immunomagnetic
beads depletion (Dynal Biotech) using a cocktail of monoclonal
antibodies (mAb): anti-CD3, anti-CD16, anti-CD19, anti-CD56
and anti-glycophorin A for monocytes purification and anti-CD14,
anti-CD16, anti-CD19, anti-CD56, and anti-glycophorin A for
lymphocytes purification (all monoclonal antibodies from Beck-
man Coulter). Monocytes were .95% enriched as assessed by
CD14 labeling and T lymphocytes .95% pure as assessed by
CD3 labeling. Monocytes (10
6 cells/mL) were differentiated to
immature DCs (iDCs) and macrophages (MDMs Macrophage-
derived monocytes) in complete RPMI 1640 medium containing
2 mM glutamine, 10 mM HEPES, 40 ng/mL gentamicin (all
from Life Technologies) and 10% FCS (Biowest), supplemented
with 40 ng/mL human recombinant granulocyte/macrophage
colony-stimulating factor (GM-CSF) plus 250 U/mL human
recombinant IL-4 for iDCs or 40 ng/mL macrophage colony-
stimulating factor (M-CSF) for MDMs (all from Abcys) and
incubated for 5 days at 37uCi n5 %C O 2.
M-hMPV binding and internalization
The binding of Fluorescein-M-hMPV was performed on
differentiated cells harvested on day 5 and resuspended in
culture medium. Different concentrations of Fluorescein-M-
hMPV were incubated with cells (10
6/mL) for 20 min on ice.
Cells were then washed and recovered in cold FACS buffer. In
competition experiments, 4.1 nM M-hMPV-Fluorescein was
incubated with cells during a 20 min period on ice, washed
twice by cold medium and an increased non-labeled concentra-
tion of M-hMPV was then added to the cells and incubated on
ice for 20 min. Those cells were then washed and recovered in
cold FACS buffer. To follow receptor-mediated endocytosis, cells
were incubated on ice for 20 min with 1.3 nM Fluorescein-M-
hMPV, washed twice at 4uC, and then incubated at 37uCf o r5
to 30 min in complete RPMI medium. Internalization was
stopped on ice with cold PBS containing 0.1% BSA and 0.05%
NaN3.2 610
5 cells of binding and internalization experiments
were added per round 12 mm diameter coverslip (Marienfeld)
coated with poly-l-lysine (Sigma) and incubated 1 h at 4uCf o r
binding and at 37uC for internalization. Cells were fixed using
4% paraformaldehyde (PFA) for 10 min, rinsed with PBS and
examined by confocal microscopy using a non inverted
Axioplan2 LSM510 Zeiss, as well as the Zeiss LSM Image
Browser software (Zeiss).
APCs phenotypic response to M-hMPV
To determine its effect, the M-hMPV recombinant protein was
added to the iDCs for 24 h. We tested the bacterial recombinant
M-hMPV protein as well as different protein controls: the protein
elution buffer, the protein treated by polymyxin B sulphate
(10 mg/mL) (Sigma), and heated at 20 min at 100uC. Also, LPS
(10 ng/mL) (from E. coli isotype 0111:B4) (Sigma) was used as a
positive control of phenotype maturation and HCV-NS3 Helicase
recombinant protein (HCV-NS3H) produced in the same
conditions as the M-hMPV protein as a negative control.
After 24 h of treatment, cell phenotype was analyzed by flow
cytometry on a FACS Calibur (BD Biosciences) using CELL-
QUEST software (Becton Dickinson) (10 000 events/test). FITC-
conjugated anti-CD14, -HLA-DR, -CD80, and phycoerythrin
(PE)-conjugated anti-CD1a, -CD86, -CD83 and -CD40 were used
to phenotype the cells (all from Immunotech). An isotypic control
was also used to set the gating for the cells.
Apoptosis measurement
1610
6 moDCs were pelleted, re-suspended in 100 mL of PBS
containing 40 nM 3,39-dihexyloxacarbocyanine iodide (DiOC6(3)
(Molecular Probes) and incubating 30 min at room temperature in
the dark. After incubation, cells were washed twice in PBS and re-
suspended in FACS buffer. The DiOC6(3) membrane potential-
related fluorescence was analyzed by flow cytometry on a FACS
Calibur.
Quantification of apoptotic nuclei was also assessed by staining
apoptotic nuclei with Propidium Iodide. Briefly, 25 mM of PI was
added to the 1610
6 DiOC6(3) labelled cells prior analysis by flow
cytometry.
Cytokine production by APCs in response to M-hMPV
protein
Supernatants from moDCs were assayed for cytokines IL-
12p70, TNF, IL-10, IL-6, IL-1b, and IL-8 and supernatants from
MDMs were assayed for chemokines MIP-1b, RANTES and TNF
by Cytometric Bead Array (CBA, BD Biosciences). IFN-a and
IFN-b were measured using ELISA kits (PBL Biomedical
Laboratories).
Mixed lymphocyte reaction (MLR). Naive T-lymphocytes were
purified from human peripheral blood as previously described in
section ‘‘Generation of monocyte-derived DCs (moDCs) and
monocyte-derived macrophages (MDMs)’’. The cell assays were
carried out in 96-well flat-bottom culture plates in triplicate for
each condition. iDCs were treated for 24 h with LPS (positive
control), HCV-NS3H protein (negative control), elution buffer and
M-hMPV protein. After incubation at 37uCi n5 %C O 2, cells were
collected, extensively washed, resuspended in RPMI 10% FCS
and then co-cultured with 2610
5 allogeneic T-cells in 200 mLo f
complete culture medium at 1:5, 1:10 or 1:20 APC: responder T-
cell ratio. After co-culture at 37uCi n5 %C O 2, supernatants were
recovered and tested for an IL-2 (day 2), IL-5, IL-13, and IFN-c
(day 5) secretion assay by Cytometric Bead Array flex (BD
Biosciences).
Immune Response to M-hMPV
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M-hMPV protein detection in the supernatant
We hypothesized that M-hMPV can be released from hMPV
infected cells. To confirm this hypothesis, we captured the protein
from the supernatant of hMPV infected Vero cells. After
ultracentrifugation to remove virus particles, anionic charge
polymers beads were used to capture the free soluble M-hMPV
(figure 1A) confirming that M-hMPV can be released during
hMPV cell infection.
To support the previous result, 293T cells were transiently
transfected by the vector phCMV encoding M-hMPV. A soluble
form of M-hMPV in the supernatant of transfected cells was
detected and analyzed. As seen in figure 1B, more than 90% of the
M-hMPV was detected in the supernatant and this was further
confirmed by the observation that after ultracentrifugation the M-
hMPV protein was still identified in the supernatant. Furthermore,
a lower amount was found in the pellet fraction. To establish
whether the M-hMPV protein was associated with the cell
membrane, we performed a flotation assay using the total cell
supernatant. As shown in figure 1C, most of the M-hMPV did not
float and stayed towards the bottom of the tube indicating that the
protein was generally not associated with cell membranes.
However, a small amount of the M protein was found in the
upper phase suggesting the presence of a possible M-hMPV form
that interacts with membranes. Under non-reducing conditions,
M-hMPV displayed a double band pattern indicating a possible
internal disulfide bridge.
M-hMPV binds APCs
Since M-hMPV is released, we investigated the potential of this
protein to interact with APCs. We produced and used an
endotoxin-free prokaryotic recombinant M-hMPV protein
(figure 2). APCs were generated in vitro by cultivating human
monocytes with differentiation factors. Analysis of the moDCs
phenotype showed that at day 5 of culture, these cells had little
expression of CD14 but high levels of CD1a and intermediate
levels of HLA-DR (figure 3). Conversely, MDMs displayed high
expression of CD14 and little expression of CD1a and the same
intermediate expression of HLA-DR. To determine the uptake of
the M-hMPV protein by moDCs, we analyzed the binding of M-
hMPV labeled with fluorescein to moDCs and to MDMs by flow
cytometry. M-hMPV bound moDCs and MDMs (figure 4A) and
this binding was dose-dependent, partially saturable for moDCs
and completely saturable for MDMs at a concentration of 2.7 nM.
When fluorescent-M-hMPV binding was competed using an
unlabeled M-hMPV at 4uC, M-hMPV was bound more efficiently
in MDMs than in moDCs (figure 4B) indicating that a receptor
may be implicated in the binding process and those MDMs had
possibly more receptors than moDCs. From this, fluorescent
M-hMPV appeared to be efficiently and rapidly internalized after
the binding at 4uC and the incubation of the cells at 37uC
(figure 4C). To further investigate the uptake of M-hMPV,
confocal microscopy (figure 4D) was used to visualize the
interaction with APCs. Analysis of the samples of APCs cultured
with fluorescent M-hMPV showed isolated clusters for MDMs as
compared to a diffuse labeling in moDCs. All together, these data
suggest the idea that M-hMPV may bind specifically to the surface
of MDMs. In contrast, for moDCs the data suggested the existence
of different receptors involved in the binding profile.
M-hMPV induces moDCs maturation
To determine the effect of M-hMPV protein on APCs, the
purified and endotoxin-free prokaryotic recombinant M-hMPV
protein was applied into immature moDCs (iDCs). After 24 h of
contact with the M-hMPV protein, the phenotype of moDCs was
analysed by flow cytometry and by measuring the expression of
CD40, CD80, CD83 and CD86 surface molecules. As shown in
figure 5, 0.0172 and 0.172 nM of M-hMPV protein were able to
induce the up-regulation of CD40, CD80, CD83 and CD86
moDCs cell surface markers in a dose-dependent manner. These
results may reflect the capacity of M-hMPV to induce phenotypic
maturation of moDCs. The negative controls, such as the HCV-
NS3 helicase recombinant protein [24], produced and purified in
the same M-hMPV conditions did not change the expression levels
of co-stimulatory molecules (data not shown). To further confirm
the induction of maturation was by M-hMPV and not through
some other mechanism, such as LPS stimulation, moDCs were
treated with polymyxin B Sulfate (10 mg/mL) prior treatment with
M-hMPV protein and, similarly, moDCs were treated with heat
Figure 1. M-hMPV protein is released both in the supernatant of hMPV infected cells and M-hMPV transiently transfected cells.
(A) M-hMPV protein was captured in the supernatant of the infected Vero cells by using positively charged magnetic beads. Samples were incubated
with 1 mg/mL monoclonal antibodies directed against M-hMPV and 1 mg/mL goat anti-mouse immunoglobulin G antibody conjugated to horseradish
peroxidase antibodies and revealed by ECL susbtrate. 1: ultracentrifugated supernatant of hMPV infected Vero cells; 2: supernatant of uninfected Vero
cells. (B) 293T cells were transiently transfected by phCMV/M-hMPV. After 48 h, the supernatant was subjected to ultracentrifugation over a 20%
sucrose cushions. The pelleted material was resuspended in PBS. Samples were analyzed by western blot in reducing condition using anti M-hMPV
antibodies. (C) A flotation assay on the supernatant of M-hMPV transfected 293T cells was performed. Fractions 1 to 5 represent sample fraction in
60% histodenz, fraction 6 to 11, 40% histodenz and fraction 12 and 13, 10% histodenz. Membrane associated proteins are found at the interface of
40% and 10%. Fractions were analyzed by western blot in non reducing condition by using anti M-hMPV antibodies.
doi:10.1371/journal.pone.0017818.g001
Immune Response to M-hMPV n itro
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I Vtreated M-hMPV protein (100uC for 20 min). Polymyxin B, which
prevents LPS activation, did not reduce the M-hMPV protein
potential to induce moDCs maturation and an up-regulation of
the cell surface markers was still observed. Furthermore, the heat
treatment inhibited the ability of M-hMPV to up-regulate the
CD40, CD80, CD83 and CD86 cell surface markers and did not
induce moDCs maturation (figure 5). M-hMPV treatment did not
induce apoptosis of moDCs (Table 1). Taken together, these
results suggest that M-hMPV protein can stimulate moDCs into
up-regulating their co-stimulatory molecules.
M-hMPV induces the production of inflammatory
mediators by APCs
In addition to the expression of surface co-stimulatory
molecules, the DCs maturation process can lead to the release of
soluble mediators, such as cytokines, which affect both humoral
and T-cell-mediated immune responses. As shown in figure 6A,
M-hMPV induced the production of IL-8, IL-6, TNF, IL-12p70,
IL-1b and IL-10 by moDCs in a dose-dependent manner.
Furthermore, since chemokines play an important role in the
initiation of immune response, we analyzed whether M-hMPV
protein impacted on the MDMs chemokine expression profile and
on the TNF cytokine. MIP-1b, RANTES and TNF were detected
in supernatants of M-hMPV treated-MDMs (figure 6B).
M-hMPV induced type I interferon response. The type I
interferons (IFNs) play an essential role in the early antiviral cell
r e s p o n s e .W i t ht h i si nm i n d ,w ei n v e s t i g a t e dt h ep o t e n t i a lf o r
M-hMPVtoinducethesemolecules.ThesecretionoftypeIIFNswas
quantified in MDMs supernatants obtained after 24 h of culture with
M-hMPV. M-hMPV treated-MDMs produced only low levels of
IFN-b (figure 7), and similarly, little secretion of IFN-a was observed.
Furthermore, neither IFN-a,n o rI F N - b were detected in the
supernatant of M-hMPV-treated moDCs (data not shown).
M-hMPV induces mature moDCs to activate allogeneic
T-cells
To further study the maturation level and the functionality of the
moDCs, we tested M-hMPV activated DC for their capacity to
stimulate the allogeneic T-cells by performing a MLR. The mature
moDCs treated with the M-hMPV protein were co-cultured with
allogeneic T-cells for either two or five days. Supernatants were
recovered and the production of IL-2 (day 2), IFN-c,I L - 5a n dI L - 1 3
(day 5) was analyzed. The allogeneic T-cells produced IFN-c in a
ratio- and dose-dependant manner (figure 8). Furthermore, IL-2 was
constantly secreted at day 2 and day 5 at about 200 pg/mL (data not
shown), but IL-5 and IL-13 were not detected (data not shown).
Figure 2. M-hMPV bacterial recombinant protein is successfully
produced. (A) SDS-PAGE analysis of M-hMPV recombinant protein was
performed after purification by Ni-NTA resin. (B) M-hMPV protein was
analyzed by western blot using M-hMPV 1 mg/mL monoclonal
antibodies and HCV monoclonal antibody for the negative control
together with species-specific secondary antibody goat anti-mouse IgG
H+L labeled with alkaline phosphatase.
doi:10.1371/journal.pone.0017818.g002
Figure 3. MoDCs express the CD1a molecule while MDMs express the CD14 molecule. Monocytes were differentiated during 5 days in
complete RPMI medium containing 40 ng/mL GM- CSF and 250 U/mL IL-4 for moDCs and 40 ng/mL M-CSF for MDMs. Phenotype of cells were
analyzed on day 5 for the expression of CD14, CD1a and HLA-DR. Data represent histograms with isotype control (bold line) and monocyte-
differentiated cells (filled profile).
doi:10.1371/journal.pone.0017818.g003
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hMPV is a major cause of respiratory tract illness especially in
young children and the need to develop new strategies to deal with
such infection remains a priority. The matrix protein is one of the
most abundant protein in the virion and its role in the
establishment of the immune response is still unknown. The
M-hMPV soluble protein was detected in the supernatant of both
hMPV infected Vero cells and transiently M-hMPV transfected
293T cells. Because the M-hMPV release has been detected in the
supernatant of cells presenting characteristic hMPV cytopathic
effects, a hypothesis could be that a process of cell death may occur
and allow the release of the matrix protein from infected cells.
Further experiments are needed to characterize the release
process.
The release from the hMPV infected cells can be the result of a
specific mechanism or of cell death. Regarding the transiently M-
hMPV transfected 293T cells, most of the protein was released as a
soluble form leaving a small proportion of the protein associated
with the cell membranes. To our knowledge, this is the first time
that a soluble viral matrix protein has been reported. The
M-hMPV protein does not have a signal peptide and may not be
able to enter the conventional secretion pathway [26]. However,
other viral proteins have been described to be secreted without
signal peptide, such as HIV tat [27,28] and HSV VP22 [29].
Moreover, it may undergo secretion through other pathways, such
as intracellular vesicular routes (exosomes formation, secretory
lysosomes) or other where intermediate intracellular vesicles are
not involved (membrane blebbing/shedding, translocation medi-
ated by plasma membrane-resident transporters) [30].
The objective of this study was to determine the M protein effect
in the immune response. To further study M-hMPV protein, an
endotoxin free M-hMPV recombinant protein was produced in
bacteria. In our model, M-hMPV protein demonstrated a dose-
dependent binding to moDCs and MDMs along with an efficient
and rapid internalization as demonstrated by confocal microscopy.
Figure 4. M-hMPV protein binds APCs and is internalized. (A) Binding experiment. APCs were incubated with increased concentrations of
M-hMPV-Fluorescein protein for 20 min at 4uC, washed and then analyzed by FACS. Data are shown as mean fluorescence intensity. (B) Competition
experiment. APCs were incubated with M-hMPV-Fluorescein protein 4.1 nM for 20 min at 4uC, washed before addition of increased concentration of
unlabeled M-hMPV protein for 20 min at 4uC. Results are shown as % of mean fluorescent intensity of M-hMPV-Fluorescein protein binding.
(C) Internalization experiment. Cells were incubated with 1.3 nM M-hMPV-Fluorescein protein during 20 min at 4uC, washed and incubated at
different time points at 37uC. Cells were then washed and analyzed. Data are shown as mean fluorescence intensity. (D) Confocal microscopy. Cells
were incubated with 0.17 nM M-hMPV protein 30 min at 4uC and then washed and incubated or not at 37uC for 30 min. Observation was realized by
confocal microscopy. Data represent one out of two experiments.
doi:10.1371/journal.pone.0017818.g004
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of co-stimulatory molecules CD40, CD80, CD83 and CD86
indicating that moDCs appeared to be activated and induced to
mature. Furthermore, the M-hMPV treatment does not induce
apoptosis of the moDCs that could explain the release of
cytokines/chemokines. This observed maturation response was
unlikely to be caused by LPS contamination as polymyxin B did
not affect M-hMPV-induced phenotypic or functional maturation.
Heating M-hMPV completely abolished its activation effects
whereas LPS is inactivated by heating. Furthermore, M-hMPV
protein did not contain detectable nucleic acid contaminants (data
not shown) that could activate a Toll-like receptor pathway.
In our in vitro model, we observed that moDCs and MDMs
treated with M-hMPV were induced to produce cytokines and
chemokines associated with their maturation and activation.
M-hMPV protein induced a dose-dependent increase of TNF
and IL-12p70 production, essential inflammatory cytokines that
have been associated with immune responses including Th1-type
[31]. The b chemokines RANTES and MIP-1b are implicated in
the modulation of different biological process, such as cellular
activation, degranulation, and enzyme release [32,33]. These
molecules have also been characterized as the key players in the
directional migration of a various number of inflammatory cell
types like neutrophils, macrophages, lymphocytes B and T
[32,34,35]. Thus, cytokines and chemokines produced by
activated APCs are indicative of the inflammatory process
generated by M-hMPV protein. These data also support the
detection of these cytokines by Laham et al. [10] in the
nasopharyngeal and the tracheal secretion of children infected
by hMPV even if the amount of secretion was less important than
with RSV. Boivin et al. firstly reported an outbreak of hMPV
infection in a long-term facility care and presented histopatholog-
ical findings associated with a fatal pneumonia case in an 89-year-
old woman [36]. Immunohistochemical staining of a lung autopsy
has been performed by using a monoclonal antibody directed
against the hMPV matrix protein and revealed evident localization
of the M protein in the cytoplasm of bronchiolar epithelial cells.
These observations support that the M-hMPV protein could elicit
a persistent innate immune response which may contribute to the
pathogenesis of bronchiolitis in infants and young children as well
as acute respiratory tract infections in elderly patients infected with
hMPV.
The complete maturation of M-hMPV treated-moDCs was
demonstrated by their ability to stimulate IFN-c synthesis by
allogeneic T cells indicating that M-hMPV protein is a
predominant Th1 promoting innate stimulus. This IFN produc-
tion is controlled by cytokines secreted by APCs, particularly by
IL-12. IFN-c up-regulates the expression of class I MHC
molecules to the cells, which is important for the immune host
response as it increases the recognition of pathogens peptides by
cytotoxic T cell and induces the cell mediated immunity [37].
The induction of type I IFN molecules is crucial in the
establishment of the innate immune response to fight a viral
infection [38]. In our experiments, the M-hMPV treated APCs
Figure 5. M-hMPV protein induces maturation of moDCs. moDCs were treated with M-hMPV protein 0.172 nM (gray filled) and 0.0172 nM
(green line), LPS 10 ng/mL (black line), M-hMPV 0.172 nM+polymyxin (orange line), M-hMPV heat treated at 100uC–20 min (pink dotted line) or
untreated (iDCs) (gray line) and the phenotype was analyzed after 24 h of treatment. Cells were stained with labeled CD80, CD83, CD86 and CD40
antibodies. Data were acquired by a FACScan and analyzed by CellQuest Pro software. Histograms represent mean fluorescence intensity. Data
shown are representative of one out of five independent experiments.
doi:10.1371/journal.pone.0017818.g005
Table 1. Percentage of apoptotic M-hMPV-treated moDCs.
Viable (%) Apoptotic (%)
iDCs 97 3
LPS 10 ng/mL 82 18
HCV NS3H 0.172 nM 92 8
M-hMPV 0.172 nM 91 9
M-hMPV 0.086 nM 95 5
M-hMPV 0.034 nM 90 10
M-hMPV 0.0172 nM 92 8
After 24 h of stimulation, M-hMPV-treated moDCs were labeled by DiOC6(3)
and propidium iodide prior analysis by flow cytometry. Data are representative
of one out of two independent experiments.
doi:10.1371/journal.pone.0017818.t001
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matrix protein did not seem to play a part in the early antiviral
immune response against hMPV. Guerrero-Plata et al. [39]
observed that hMPV infection of moDCs resulted in the release
of IFN-a when RSV-infected moDCs failed to produce it.
However, both viruses were capable to interfere with IFN-a
secretion induced by specific agonists. RSV has been reported as a
poor inducer of type I IFN due to the two non-structural proteins
NS1 and NS2. Spann et al. [40] showed that RSV NS1 and NS2
proteins function independently and co-ordinately to inhibit the
IFN production, with NS1 having a greater independent role.
hMPV lacks these proteins in its genome but recently, the hMPV
glycoprotein G has been identified as a potential inhibitor of the
IFN production in airway epithelial cells. Bao et al. [41]
demonstrated that hMPV is a poor inducer of type I IFN. The
hMPV glycoprotein G has been identified as an important virulence factor that
interacts with and inhibits the activation of RIG-I, an RNA
helicase which is involved in the signaling cascade leading to
NF-kB, IRF activation and IFN production. The glycoprotein G
Figure 6. MoDCs and MDMs treated with M-hMPV protein produce high level of cytokines and chemokines respectively.
(A) Supernatants of cells treated for 24 h with elution buffer, LPS 10 ng/mL (positive control) and M-hMPV 0.172, 0.086, 0.034, 0.0172 nM were
assayed for the level of IL-8, IL-6, TNF, IL-12p70, IL-1b and IL-10 cytokines by CBA. (B) Supernatant of MDMs treated with elution buffer, LPS 10 ng/mL
(positive control), M-hMPV 0.172 and 0.0172 nM were assayed for MIP-1b, RANTES and TNF production by CBA. Bar graph represents concentrations
values expressed in ng/mL. Data are represented as means of three experiments 6 S.D.
doi:10.1371/journal.pone.0017818.g006
Figure 7. M-hMPV treated-MDMs release low level of IFN-a and
IFN-b. MDMs were treated with elution buffer, LPS 10 ng/mL, M-hMPV
0.172 and 0.0172 nM. Supernatants were collected after 24 h and tested
for IFN-a and IFN-b production by ELISA. Bar graph represents
concentrations values expressed in pg/mL. Data are represented as
means of three experiments 6 S.D.
doi:10.1371/journal.pone.0017818.g007
Figure 8. M-hMPV activated-DCs present antigen to T cells
which induce the production of IFN-c. moDCs were treated for
24 h with LPS 10 ng/mL and M-hMPV protein 0.344, 0.172, 0.086,
0.034 nM. Cells were harvested after treatment, washed and cultured
for 5 days with allogeneic purified T-cells (2610
5/well) at a DC/T ratio
ranging between 1:5 and 1:40. The amount of IFN-c in the cell-free
supernatants of the co-culture was measured by ELISA. Data are
represented as means of three experiments 6 S.D.
doi:10.1371/journal.pone.0017818.g008
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like the IFNs. Depending of the cell type, hMPV induces or not a
production of type I IFN. It may be of some interest to determine
if the M-hMPV protein can act like the glycoprotein G and
inhibits the IFNs production by interacting with a sensor of viral
infection in DCs.
Tan et al. [42] demonstrated that hMPV induces an impaired
allo-stimulatory function of dendritic cells, consequently causing a
poor production of inflammatory cytokines. In contrast, Guerrero-
Plata et al. [39] showed that hMPV-infected moDCs did not
significantly inhibit T cell proliferation. They also demonstrated
that RSV and hMPV differentially activate human DCs. Both
viruses were able to mature moDCs characterized by an up-
regulation of antigen-presenting and co-stimulatory molecules,
however, only RSV-infected moDCs led to impaired T cell
activation. This finding has also been observed by de Graaff et al.
[43] including data demonstrating a failure for T cell activated by
RSV-DC to produce IFN-c. hMPV is a major respiratory
pathogen in infants and in the elderly as well as RSV, two
genetically distinct members of the Paramyxoviridae family that
cause indistinguishable clinical symptoms. However, data dis-
cussed previously, demonstrate a difference in the immune
response. It is interesting that, unlike RSV, hMPV did not
stimulate the production of inflammatory cytokines, hMPV-
infected DC were able to stimulate T cells [39] but did elicit
identical inflammatory symptoms of similar [44] or milder severity
[45]. A critical question raised by these studies is the different
properties of hMPV isolates used to infect and replicate into APCs.
In tissue culture, growth of hMPV is slow and requires the
addition of trypsin to the media to efficiently propagate the virus
[1,4]. This difficulty and the adaptation of the virus strain in vitro
may explain the paradigm of the results obtained by Guerrero-
Plata et al. and Tan et al. in their studies.
The primary defense barriers against pathogens, such as viral
particles or proteins of pathogens, are built up by epithelial
surfaces in contact with APCs. We hypothesized that hMPV
infection in pulmonary epithelial cells may lead to the release of
M-hMPV protein stimulating the APCs resident in the respiratory
tract. M-hMPV could then selectively and efficiently be processed
by APCs. Moreover, M-hMPV induces their maturation,
promotes their capacity to stimulate T lymphocytes and finally
elicits a predominant Th1 pattern of response.
In conclusion, we demonstrate for the first time that M-hMPV
protein can be released in a soluble form and that it can interact
with human moDCs and MDMs inducing a response. These
M-hMPV/APCs interactions were characterized by (1) the
binding and internalization of M-hMPV to human APCs in a
dose-dependent manner; (2) the up-regulation of moDCs co-
stimulatory molecules CD40, CD80, CD83 and CD86; (3) the
secretion of inflammatory mediators IL-8, IL-6, TNF, IL-12p70,
IL-1b and IL-10; and (4) the stimulation of T cells by moDCs
activated by M-hMPV inducing a predominant Th1 polarization
and demonstrating an efficient M-hMPV innate stimulus. These
finding suggest that M-hMPV plays a central role in the
inflammatory response initiated by the host innate immune system
and is highly intertwined in the mechanisms of respiratory
pathogenesis.
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